TY - JOUR
T1 - Clinically Significant Axial Shortening in Myopic Children After Repeated Low-Level Red Light Therapy
T2 - A Retrospective Multicenter Analysis
AU - Wang, Wei
AU - Jiang, Yu
AU - Zhu, Zhuoting
AU - Zhang, Shiran
AU - Xuan, Meng
AU - Chen, Yanping
AU - Xiong, Ruilin
AU - Bulloch, Gabriella
AU - Zeng, Junwen
AU - Morgan, Ian G.
AU - He, Mingguang
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/4
Y1 - 2023/4
N2 - Introduction: Myopia is recognized as a progressive eye disease. The aim of this study was to evaluate the frequency and associated factors of clinically significant axial length (AL) shortening among myopic children following repeated low-level red light (RLRL) therapy. Methods: The clinical data that were collected for the myopic children aged 3–17 years who received an RLRL therapy delivered by home-use desktop light device that emitted light at 650 nm for at least 1 year, were reviewed. The clinical data included AL, spherical equivalent refraction (SER), and visual acuity measured at baseline and follow-up. The primary outcomes were frequency of AL shortening of > 0.05 mm, > 0.10 mm, and > 0.20 mm per year, and associated factors of AL shortening per year. Results: A total of 434 myopic children with at least 12 months of follow-up data were included. The mean age of participants was 9.7 (2.6) years with SER of −3.74 (2.60) diopters. There were 115 (26.50%), 76 (17.51%), and 20 (4.61%) children with AL shortening based on cutoffs of 0.05 mm/year, 0.10 mm/year, and 0.20 mm/year, respectively. In the multivariable model, AL shortening was significantly associated with older baseline age, female gender, and longer baseline AL or greater spherical equivalent refraction (all P < 0.05). Among AL shortened eyes, the mean AL difference (standard deviation, SD) was −0.142 (0.094) mm/year. Greater AL shortening was observed among children who were younger and had longer baseline AL (all P < 0.05). Conclusions: More than a quarter of children had AL shortening > 0.05 mm following RLRL therapy, and the overall mean AL change was −0.142 mm/year. Further studies should explore the mechanisms underlying AL shortening.
AB - Introduction: Myopia is recognized as a progressive eye disease. The aim of this study was to evaluate the frequency and associated factors of clinically significant axial length (AL) shortening among myopic children following repeated low-level red light (RLRL) therapy. Methods: The clinical data that were collected for the myopic children aged 3–17 years who received an RLRL therapy delivered by home-use desktop light device that emitted light at 650 nm for at least 1 year, were reviewed. The clinical data included AL, spherical equivalent refraction (SER), and visual acuity measured at baseline and follow-up. The primary outcomes were frequency of AL shortening of > 0.05 mm, > 0.10 mm, and > 0.20 mm per year, and associated factors of AL shortening per year. Results: A total of 434 myopic children with at least 12 months of follow-up data were included. The mean age of participants was 9.7 (2.6) years with SER of −3.74 (2.60) diopters. There were 115 (26.50%), 76 (17.51%), and 20 (4.61%) children with AL shortening based on cutoffs of 0.05 mm/year, 0.10 mm/year, and 0.20 mm/year, respectively. In the multivariable model, AL shortening was significantly associated with older baseline age, female gender, and longer baseline AL or greater spherical equivalent refraction (all P < 0.05). Among AL shortened eyes, the mean AL difference (standard deviation, SD) was −0.142 (0.094) mm/year. Greater AL shortening was observed among children who were younger and had longer baseline AL (all P < 0.05). Conclusions: More than a quarter of children had AL shortening > 0.05 mm following RLRL therapy, and the overall mean AL change was −0.142 mm/year. Further studies should explore the mechanisms underlying AL shortening.
KW - Axial length
KW - Myopia
KW - Repeated low-level red light (RLRL) therapy
KW - Retrospective study
KW - Reverse
UR - http://www.scopus.com/inward/record.url?scp=85145852436&partnerID=8YFLogxK
U2 - 10.1007/s40123-022-00644-2
DO - 10.1007/s40123-022-00644-2
M3 - Article
SN - 2193-8245
VL - 12
SP - 999
EP - 1011
JO - Ophthalmology and Therapy
JF - Ophthalmology and Therapy
IS - 2
ER -